Isoxsuprine

Isoxsuprine
Clinical data
Pronunciation	/aɪˈsɒksjʊpriːn/
Trade names	Duvadilan, Vasodilan
MedlinePlus	a682831
Routes of; administration	Oral (tablets)
ATC code	C04AA01 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	~100% (humans), 2.2% (horses; oral)
Onset of action	1 hour
Elimination half-life	<3 hours (horses)
Excretion	Mainly renal
Identifiers
	IUPAC name 4-{1-Hydroxy-2-[(1-methyl-2-phenoxyethyl)amino]propyl}phenol;
CAS Number	395-28-8;
PubChem CID	3783;
DrugBank	DB08941;
ChemSpider	3651 ;
UNII	R15UI3245N;
KEGG	D08092 ;
ChEMBL	ChEMBL1197051 ;
CompTox Dashboard (EPA)	DTXSID9023178 ;
ECHA InfoCard	100.006.272
Chemical and physical data
Formula	C18H23NO3
Molar mass	301.386 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O(c1ccccc1)CC(NC(C)C(O)c2ccc(O)cc2)C;
	InChI InChI=1S/C18H23NO3/c1-13(12-22-17-6-4-3-5-7-17)19-14(2)18(21)15-8-10-16(20)11-9-15/h3-11,13-14,18-21H,12H2,1-2H3 ; Key:BMUKKTUHUDJSNZ-UHFFFAOYSA-N ;

Isoxsuprine (used as isoxsuprine hydrochloride) is a drug used as a vasodilator^[4] in humans (under the trade name Duvadilan) and equines. Isoxsuprine is a β₂ adrenoreceptor agonist that causes direct relaxation of uterine and vascular smooth muscle via β₂ receptors.^[5]

^ McGuigan MA, Whyte IM, Dawson AH, Seifert SA, Schonwald S, Yip L, et al. (2004). "125. Vasodilators". In Dart RC (ed.). Medical Toxicology (3rd ed.). Philadelphia [u.a.]: Lippincott Williams & Wilkins. p. 718. ISBN 978-0781728454.
^ Erkert RS, Macallister CG (April 2002). "Isoxsuprine hydrochloride in the horse: a review". Journal of Veterinary Pharmacology and Therapeutics. 25 (2): 81–87. doi:10.1046/j.1365-2885.2002.00386.x. PMID 12000527.
^ Cole C, Bentz B, Maxwell L, eds. (2014). "13. Clinical pharmacology of the equine musculoskeletal system". Equine Pharmacology. Wiley—Blackwell. p. 224. ISBN 978-0-8138-2262-4.
^ Gozo EG, Yebes RB (November 1984). "Hemodynamic effects of isoxsuprine in cardiac failure". Chest. 86 (5): 736–40. doi:10.1378/chest.86.5.736. PMID 6488912.
^ Falkay G, Kovács L (1986). "Affinity of tocolytic agents on human placental and myometrial beta-adrenergic receptors". Journal of Perinatal Medicine. 14 (2): 109–13. doi:10.1515/jpme.1986.14.2.109. PMID 2874205. S2CID 6039919.

[1] McGuigan MA, Whyte IM, Dawson AH, Seifert SA, Schonwald S, Yip L, et al. (2004). "125. Vasodilators". In Dart RC (ed.). Medical Toxicology (3rd ed.). Philadelphia [u.a.]: Lippincott Williams & Wilkins. p. 718. ISBN 978-0781728454.

[2] Erkert RS, Macallister CG (April 2002). "Isoxsuprine hydrochloride in the horse: a review". Journal of Veterinary Pharmacology and Therapeutics. 25 (2): 81–87. doi:10.1046/j.1365-2885.2002.00386.x. PMID 12000527.

[3] Cole C, Bentz B, Maxwell L, eds. (2014). "13. Clinical pharmacology of the equine musculoskeletal system". Equine Pharmacology. Wiley—Blackwell. p. 224. ISBN 978-0-8138-2262-4.

[pmid6488912-4] Gozo EG, Yebes RB (November 1984). "Hemodynamic effects of isoxsuprine in cardiac failure". Chest. 86 (5): 736–40. doi:10.1378/chest.86.5.736. PMID 6488912.

[5] Falkay G, Kovács L (1986). "Affinity of tocolytic agents on human placental and myometrial beta-adrenergic receptors". Journal of Perinatal Medicine. 14 (2): 109–13. doi:10.1515/jpme.1986.14.2.109. PMID 2874205. S2CID 6039919.

[1]

[2]

[3]

[4]

[5]